Equities research analysts at Sanford C. Bernstein started coverage on shares of The Coca-Cola (NYSE:KO) in a research report issued on Tuesday, The Fly reports. The firm set an "outperform" rating on the stock.
Several other research analysts have also commented on the stock. UBS Group boosted their price objective on shares of The Coca-Cola from $54.00 to $57.00 and gave the stock a "buy" rating in a research note on Friday, October 23rd. Deutsche Bank Aktiengesellschaft downgraded shares of The Coca-Cola from a "buy" rating to a "hold" rating and dropped their target price for the stock from $57.00 to $55.00 in a research report on Tuesday, January 5th. HSBC dropped their target price on shares of The Coca-Cola from $61.00 to $58.00 in a research report on Wednesday, January 13th. Morgan Stanley dropped their target price on shares of The Coca-Cola from $59.00 to $55.00 and set an "overweight" rating on the stock in a research report on Thursday, January 14th. Finally, Royal Bank of Canada downgraded shares of The Coca-Cola from an "outperform" rating to a "sector perform" rating and set a $55.00 target price on the stock. in a research report on Monday, January 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. The company currently has an average rating of "Buy" and a consensus price target of $54.18.
Shares of NYSE KO traded down $0.25 during trading hours on Tuesday, hitting $48.45. 1,468,025 shares of the stock were exchanged, compared to its average volume of 28,294,240. The company has a quick ratio of 1.01, a current ratio of 1.13 and a debt-to-equity ratio of 1.94. The company has a market cap of $208.21 billion, a PE ratio of 25.23, a PEG ratio of 5.70 and a beta of 0.58. The firm has a fifty day moving average price of $52.77 and a 200-day moving average price of $50.01. The Coca-Cola has a 12 month low of $36.27 and a 12 month high of $60.13.
The Coca-Cola (NYSE:KO) last posted its quarterly earnings data on Thursday, October 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.46 by $0.09. The firm had revenue of $8.65 billion during the quarter, compared to analyst estimates of $8.37 billion. The Coca-Cola had a net margin of 24.90% and a return on equity of 41.37%. The Coca-Cola's revenue was down 9.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.56 EPS. As a group, equities analysts anticipate that The Coca-Cola will post 1.88 earnings per share for the current fiscal year.
In related news, Director David B. Weinberg sold 200,000 shares of the business's stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $50.12, for a total value of $10,024,000.00. Following the completion of the transaction, the director now directly owns 355,214 shares in the company, valued at approximately $17,803,325.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David B. Weinberg sold 100,000 shares of the company's stock in a transaction on Monday, November 9th. The stock was sold at an average price of $52.65, for a total transaction of $5,265,000.00. Following the transaction, the director now owns 355,214 shares of the company's stock, valued at $18,702,017.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 400,000 shares of company stock valued at $20,264,000. Company insiders own 1.01% of the company's stock.
A number of large investors have recently bought and sold shares of KO. Your Advocates Ltd. LLP raised its position in The Coca-Cola by 62.3% during the third quarter. Your Advocates Ltd. LLP now owns 534 shares of the company's stock worth $26,000 after acquiring an additional 205 shares during the period. Holloway Wealth Management LLC acquired a new position in The Coca-Cola during the third quarter worth $37,000. Baron Financial Group LLC acquired a new position in The Coca-Cola during the third quarter worth $38,000. JustInvest LLC raised its position in shares of The Coca-Cola by 5.7% in the fourth quarter. JustInvest LLC now owns 24,606 shares of the company's stock valued at $48,000 after buying an additional 1,323 shares during the last quarter. Finally, Dimension Capital Management LLC acquired a new stake in shares of The Coca-Cola in the third quarter valued at about $58,000. Institutional investors own 65.99% of the company's stock.
The Coca-Cola Company Profile
The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks; water, enhanced water, and sports drinks; juice, dairy, and plantÂ-based beverages; tea and coffee; and energy drinks. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores.
Featured Article: What is the 52-week high/low?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Healthcare Stocks that Analysts Love
There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems, and other healthcare stocks, it can be hard to identify which healthcare companies will outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same healthcare stock.
This slide show lists the 15 healthcare companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Healthcare Stocks that Analysts Love".